NCT06673017 - PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

June 30, 2028

Conditions

Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma

Interventions

DRUG

PTM-101

PTM-101, an absorbable drug product containing paclitaxel

Trial Locations (5)

RECRUITING

Northwell Health Zuckerberg Cancer Center, Lake Success

RECRUITING

Karmanos Cancer Institute, Detroit

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

RECRUITING

Hoag Memorial Hospital Presbyterian, Newport Beach

RECRUITING

Virginia Mason Medical Center, Seattle